Cargando…

The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19

Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capil...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaeger, Beate Roxane, Arron, Hayley Emma, Kalka-Moll, Wiltrud M., Seidel, Dietrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592739/
https://www.ncbi.nlm.nih.gov/pubmed/36304538
http://dx.doi.org/10.3389/fcvm.2022.1007636
_version_ 1784814995918290944
author Jaeger, Beate Roxane
Arron, Hayley Emma
Kalka-Moll, Wiltrud M.
Seidel, Dietrich
author_facet Jaeger, Beate Roxane
Arron, Hayley Emma
Kalka-Moll, Wiltrud M.
Seidel, Dietrich
author_sort Jaeger, Beate Roxane
collection PubMed
description Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capillaries show inflammatory and procoagulatory activation with cell necrosis, thrombi, and massive fibrinoid deposits, namely, unsolvable microthrombi, which results in an obstructed gas exchange. Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) apheresis solves these problems by helping the entire macro- and microcirculation extracorporeally. It uses unfractionated heparin, which binds the spike protein and thereby should remove the virus (debris). It dissolves the forming microthrombi without bleeding risk. It removes large amounts of fibrinogen (coagulation protein), which immediately improves the oxygen supply in the capillaries. In addition, it removes the precursors of both the procoagulatory and the fibrinolytic cascade, thus de-escalating the entire hemostaseological system. It increases myocardial, cerebral, and pulmonary blood flow rates, and coronary flow reserve, facilitating oxygen exchange in the capillaries, without bleeding risks. Another factor in COVID is the “cytokine storm” harming microcirculation in the lungs and other organs. Intervention by H.E.L.P. apheresis could prevent uncontrollable coagulation and inflammatory activity by removing cytokines such as interleukin (IL)-6, IL-8, and TNF-α, and reduces C-reactive protein, and eliminating endo- and ecto-toxins, without touching protective IgM/IgG antibodies, leukocyte, or platelet function. The therapy can be used safely in combination with antiviral drugs, antibiotics, anticoagulants, or antihypertensive drugs. Long-term clinical experience with H.E.L.P. apheresis shows it cannot inflict harm upon patients with COVID-19.
format Online
Article
Text
id pubmed-9592739
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95927392022-10-26 The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19 Jaeger, Beate Roxane Arron, Hayley Emma Kalka-Moll, Wiltrud M. Seidel, Dietrich Front Cardiovasc Med Cardiovascular Medicine Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capillaries show inflammatory and procoagulatory activation with cell necrosis, thrombi, and massive fibrinoid deposits, namely, unsolvable microthrombi, which results in an obstructed gas exchange. Heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.) apheresis solves these problems by helping the entire macro- and microcirculation extracorporeally. It uses unfractionated heparin, which binds the spike protein and thereby should remove the virus (debris). It dissolves the forming microthrombi without bleeding risk. It removes large amounts of fibrinogen (coagulation protein), which immediately improves the oxygen supply in the capillaries. In addition, it removes the precursors of both the procoagulatory and the fibrinolytic cascade, thus de-escalating the entire hemostaseological system. It increases myocardial, cerebral, and pulmonary blood flow rates, and coronary flow reserve, facilitating oxygen exchange in the capillaries, without bleeding risks. Another factor in COVID is the “cytokine storm” harming microcirculation in the lungs and other organs. Intervention by H.E.L.P. apheresis could prevent uncontrollable coagulation and inflammatory activity by removing cytokines such as interleukin (IL)-6, IL-8, and TNF-α, and reduces C-reactive protein, and eliminating endo- and ecto-toxins, without touching protective IgM/IgG antibodies, leukocyte, or platelet function. The therapy can be used safely in combination with antiviral drugs, antibiotics, anticoagulants, or antihypertensive drugs. Long-term clinical experience with H.E.L.P. apheresis shows it cannot inflict harm upon patients with COVID-19. Frontiers Media S.A. 2022-10-11 /pmc/articles/PMC9592739/ /pubmed/36304538 http://dx.doi.org/10.3389/fcvm.2022.1007636 Text en Copyright © 2022 Jaeger, Arron, Kalka-Moll and Seidel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Jaeger, Beate Roxane
Arron, Hayley Emma
Kalka-Moll, Wiltrud M.
Seidel, Dietrich
The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
title The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
title_full The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
title_fullStr The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
title_full_unstemmed The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
title_short The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19
title_sort potential of heparin-induced extracorporeal ldl/fibrinogen precipitation (h.e.l.p.)-apheresis for patients with severe acute or chronic covid-19
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592739/
https://www.ncbi.nlm.nih.gov/pubmed/36304538
http://dx.doi.org/10.3389/fcvm.2022.1007636
work_keys_str_mv AT jaegerbeateroxane thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT arronhayleyemma thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT kalkamollwiltrudm thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT seideldietrich thepotentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT jaegerbeateroxane potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT arronhayleyemma potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT kalkamollwiltrudm potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19
AT seideldietrich potentialofheparininducedextracorporealldlfibrinogenprecipitationhelpapheresisforpatientswithsevereacuteorchroniccovid19